167 institute-for-renewable-energy uni jobs at King's College London in United Kingdom
Sort by
Refine Your Search
-
residences, managing the use of energy and water to reduce the University’s effect on the environment. Providing a wide range of support services including catering, cleaning, portaging, postal and security
-
project will focus on understanding sex differences in a mouse model of beta cell endoplasmic reticulum stress. The post holder will use a wide range of in vitro and in vivo techniques including small
-
of condensed matter, theoretical particle physics and cosmology; and experimental particle and astroparticle physics. About the role We are seeking to appoint a biophysicist or a cell/molecular biologist
-
Therapy & Regenerative Medicine (CGTRM), in partnership with KCL Gene Therapy Vector Facility (GTVF), manufactures ATMPs for a wide variety of novel gene and cell therapies for the treatment of cancers
-
novel gene and cell therapies for the treatment of cancers to rare diseases. This is an opportunity to work within one of the largest academic GMP facilities in Europe focusing on the delivery of gene
-
interested in different aspects of single molecule mechanobiology. The candidate will work with single molecule AFM and magnetic tweezers to study the nanomechanical properties of cell-cell junction proteins
-
(BHF) Centre of Research Excellence was established through a national competition in April 2008 and was successfully renewed in 2014, 2019 and 2024. The mission of the Centre is to improve outcomes
-
About us The role will be located in the Institute of Pharmaceutical Science, Waterloo Campus, which is part of the Faculty of Life Science & Medicine. The Faculty of Life Science & Medicine
-
Therapy & Regenerative Medicine (CGTRM) in collaboration with the KCL Gene Therapy Vector Facility (GTVF) develops and manufactures ATMPs for a wide variety of novel gene and cell therapies
-
molecular basis for DQ6-conferred susceptibility could lead to novel disease prevention strategies including refinements to antigen-specific immunotherapy approaches or adoptive Treg cell therapies